All Updates

All Updates

icon
Filter
FDA approval
Bluebird Bio’s sickle-cell gene therapy receives FDA approval
Cell & Gene Therapy
Dec 8, 2023
This week:
Product updates
Nintendo ventures into MMOs with new Switch Online game playtest
Metaverse Experience Platforms
Yesterday
Product updates
HP releases texture library for 3D printing with CoreTechnologie 4D Additive
Additive Manufacturing
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Smart Factory
Oct 21, 2024
Product updates
xAI launches API for third-party developers to access Grok models
Foundation Models
Oct 21, 2024
Partnerships
Nava Benefits partners with OpenAI to launch AI-powered benefits assistant
Foundation Models
Oct 21, 2024
Product updates
IBM releases Granite 3.0 AI models for enterprise use
Foundation Models
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Foundation Models
Oct 21, 2024
M&A
Inflection AI acquires Boundaryless for undisclosed sum to accelerate enterprise AI deployments
Foundation Models
Oct 21, 2024
Industry news
News Corp sues Perplexity AI for alleged copyright infringement
Generative AI Applications
Oct 21, 2024
Product updates
Haiper debuts new video generation model
Generative AI Applications
Oct 21, 2024
Cell & Gene Therapy

Cell & Gene Therapy

Dec 8, 2023

Bluebird Bio’s sickle-cell gene therapy receives FDA approval

FDA approval

  • Gene therapy company Bluebird Bio has received FDA approval for its one-time gene therapy, LYFGENIA, for the treatment of sickle-cell disease in patients 12 years and older who have experienced vaso-occlusive events (VOEs). The drug, which is priced at USD 3.1 million, will be available in the market in early 2024.

  • LYFGENIA helps treat sickle-cell disease by integrating a functional β-globin gene into patients' blood stem cells. This process potentially enables sustainable production of adult hemoglobin with anti-sickling properties, reducing VOEs, and blood vessel blockage, causing tissue damage and pain. It is a notably custom-designed therapy to treat the root cause of sickle-cell disease. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.